Details

Autor(en) / Beteiligte

• Tsuji, Masahiro
• Sawada, Mariko
• Watabe, Shinichi
• Sano, Hiroyuki
• Kanai, Masayo
• Tanaka, Emi
• Ohnishi, Satoshi
• Sato, Yoshiaki
• Sobajima, Hisanori
• Hamazaki, Takashi
• Mori, Rintaro
• Oka, Akira
• Ichiba, Hiroyuki
• Hayakawa, Masahiro
• Kusuda, Satoshi
• Tamura, Masanori
• Nabetani, Makoto
• Shintaku, Haruo

Titel

Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety

Ist Teil von

• Scientific reports, 2020-03, Vol.10 (1), p.4603-4603, Article 4603

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2020

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Neonatal hypoxic-ischaemic encephalopathy (HIE) is a serious condition; many survivors develop neurological impairments, including cerebral palsy and intellectual disability. Preclinical studies show that the systemic administration of umbilical cord blood cells (UCBCs) is beneficial for neonatal HIE. We conducted a single-arm clinical study to examine the feasibility and safety of intravenous infusion of autologous UCBCs for newborns with HIE. When a neonate was born with severe asphyxia, the UCB was collected, volume-reduced, and divided into three doses. The processed UCB was infused at 12-24, 36-48, and 60-72 hours after the birth. The designed enrolment was six newborns. All six newborns received UCBC therapy strictly adhering to the study protocol together with therapeutic hypothermia. The physiological parameters and peripheral blood parameters did not change much between pre- and postinfusion. There were no serious adverse events that might be related to cell therapy. At 30 days of age, the six infants survived without circulatory or respiratory support. At 18 months of age, neurofunctional development was normal without any impairment in four infants and delayed with cerebral palsy in two infants. This pilot study shows that autologous UCBC therapy is feasible and safe.